Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Blue Light Cystoscopy With Cysview® Registry

← catalyst calendar

NCT02660645 · readout ≤ 865 d

Sponsored by Photocure (industry) · PHO.OL — their whole pipeline →. With Catalyst Pharmaceutical Research.

Phase
Status
Recruiting
Study type
Observational
Enrollment
4,400estimated
Sites
23
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
StartApr 2014not statedWhen the study began enrolling
Primary completionDec 2028estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionDec 2028estimatedThe whole study's end, after follow-up
First posted2016-01-21estimatedWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-12-18actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Bladder Cancer

Interventions

  • Drug: Hexaminolevulinate hydrochloride (HCL) — also filed as Cysview®, Hexvix®
  • Device: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system

Primary outcome

what the primary-completion date above is the date OF
Rate of detection of bladder malignancies
measured 5 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PHO.OL's whole pipeline · Catalyst calendar · Every registered study · What changed